Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 02 11:00AM ET
139.23
Dollar change
+1.26
Percentage change
0.91
%
IndexS&P 500 P/E31.47 EPS (ttm)4.42 Insider Own0.42% Shs Outstand287.33M Perf Week4.03%
Market Cap39.96B Forward P/E22.76 EPS next Y6.12 Insider Trans-3.05% Shs Float286.12M Perf Month6.85%
Income1.29B PEG3.93 EPS next Q1.27 Inst Own90.59% Short Float1.14% Perf Quarter0.19%
Sales6.51B P/S6.14 EPS this Y5.16% Inst Trans-1.12% Short Ratio1.94 Perf Half Y5.96%
Book/sh20.68 P/B6.73 EPS next Y9.95% ROA11.40% Short Interest3.27M Perf Year8.94%
Cash/sh4.63 P/C30.06 EPS next 5Y8.00% ROE21.95% 52W Range124.16 - 155.35 Perf YTD0.14%
Dividend Est.1.00 (0.72%) P/FCF29.10 EPS past 5Y5.64% ROI13.95% 52W High-10.38% Beta1.07
Dividend TTM0.94 (0.68%) Quick Ratio1.58 Sales past 5Y5.04% Gross Margin57.85% 52W Low12.14% ATR (14)3.53
Dividend Ex-DateDec 31, 2024 Current Ratio2.09 EPS Y/Y TTM5.34% Oper. Margin24.21% RSI (14)59.67 Volatility3.08% 2.72%
Employees18100 Debt/Eq0.57 Sales Y/Y TTM-4.73% Profit Margin19.80% Recom2.33 Target Price148.93
Option/ShortYes / Yes LT Debt/Eq0.57 EPS Q/Q-24.75% Payout21.31% Rel Volume0.59 Prev Close137.97
Sales Surprise1.10% EPS Surprise3.54% Sales Q/Q0.77% EarningsNov 25 AMC Avg Volume1.69M Price139.23
SMA203.73% SMA501.17% SMA2000.45% Trades Volume266,416 Change0.91%
Date Action Analyst Rating Change Price Target Change
Aug-28-24Initiated Wells Fargo Overweight $157
Jul-10-24Upgrade Citigroup Neutral → Buy $135 → $150
Jun-27-24Downgrade Wolfe Research Outperform → Peer Perform
Jun-03-24Resumed Jefferies Hold $135
Apr-05-24Upgrade Stifel Hold → Buy $145 → $163
Dec-13-23Initiated Wolfe Research Outperform $140
Dec-12-23Downgrade BofA Securities Buy → Neutral $130 → $133
Nov-17-23Downgrade UBS Buy → Neutral $163 → $125
Sep-28-23Initiated Bernstein Mkt Perform $123
Jul-31-23Downgrade Evercore ISI Outperform → In-line $126 → $124
Nov-26-24 04:24PM
02:58PM
10:16AM
09:12AM
02:01AM
06:00PM Loading…
Nov-25-24 06:00PM
05:15PM
05:11PM
04:30PM
04:05PM
09:01AM
Nov-24-24 02:00PM
05:00AM
Nov-22-24 09:00AM
Nov-20-24 04:05PM
11:46AM Loading…
11:46AM
09:15AM
08:00AM
Nov-19-24 04:29PM
Nov-14-24 03:02PM
08:00AM
Nov-06-24 08:00AM
Oct-24-24 07:07PM
Oct-21-24 02:00AM
Oct-16-24 04:50PM
04:30PM
Oct-09-24 10:15AM
Oct-03-24 09:00PM
Sep-30-24 05:17PM
Sep-23-24 09:30AM
11:30AM Loading…
Sep-20-24 11:30AM
11:01AM
09:47AM
06:11AM
Sep-18-24 04:20PM
Sep-12-24 08:44AM
Sep-10-24 05:00PM
Sep-09-24 03:57PM
08:00AM
Sep-02-24 07:33AM
Aug-31-24 01:04AM
Aug-28-24 09:34AM
Aug-26-24 09:15AM
Aug-23-24 03:00PM
Aug-22-24 12:50PM
09:51AM
Aug-21-24 09:28PM
08:53PM
06:00PM
05:15PM
04:13PM
04:05PM
Aug-20-24 10:29AM
09:01AM
Aug-19-24 10:18AM
Aug-18-24 02:00PM
Aug-16-24 09:15AM
Aug-15-24 08:00AM
Aug-14-24 10:00AM
Aug-12-24 12:58PM
Aug-02-24 08:00AM
Jul-31-24 07:25PM
Jul-30-24 01:01PM
Jul-29-24 09:55AM
Jul-26-24 03:35PM
Jul-25-24 04:09PM
Jul-24-24 07:24AM
Jul-23-24 06:33AM
Jul-22-24 11:19AM
10:47AM
09:01AM
Jul-21-24 09:12PM
Jul-19-24 08:46AM
Jul-16-24 04:01PM
Jul-13-24 12:05PM
Jul-01-24 01:04PM
09:01AM
Jun-28-24 11:30AM
Jun-27-24 12:06PM
09:48AM
Jun-26-24 10:07AM
Jun-21-24 03:10AM
Jun-14-24 06:54AM
Jun-06-24 12:01PM
Jun-03-24 11:27AM
11:00AM
May-31-24 07:34PM
May-30-24 04:24PM
02:36PM
12:15PM
11:58AM
11:34AM
07:47AM
07:39AM
07:34AM
06:38AM
May-29-24 08:53PM
06:00PM
05:15PM
04:14PM
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCDONNELL PADRAIGPresident and CEOSep 27 '24Sale150.00477,05024,071Sep 30 01:08 PM
Grau DominiqueSenior Vice PresidentSep 26 '24Sale145.009,9901,448,55040,011Sep 27 05:02 PM
Grau DominiqueSenior Vice PresidentSep 26 '24Sale145.005,010726,45046,762Sep 27 05:02 PM
MCDONNELL PADRAIGOfficerSep 27 '24Proposed Sale150.00477,050Sep 27 12:19 PM
Grau DominiqueOfficerSep 26 '24Proposed Sale145.0015,0002,175,000Sep 26 02:52 PM
MCDONNELL PADRAIGPresident and CEOAug 22 '24Sale145.001,958283,91024,118Aug 23 11:43 AM
MCDONNELL PADRAIGOfficerAug 22 '24Proposed Sale145.001,958283,910Aug 22 12:39 PM
MCDONNELL PADRAIGPresident and CEOJul 26 '24Sale140.001,958274,12026,076Jul 30 10:42 AM
MCDONNELL PADRAIGOfficerJul 26 '24Proposed Sale140.001,958274,120Jul 26 10:56 AM
MCDONNELL PADRAIGPresident and CEOJun 18 '24Sale135.001,958264,33028,034Jun 20 06:54 PM
Grau DominiqueSenior Vice PresidentJun 10 '24Sale133.2815,0001,999,26249,486Jun 12 10:40 AM
MCDONNELL PADRAIGPresident and CEOJun 03 '24Sale130.001,958254,54025,185Jun 05 10:08 AM
Binns PhilipSenior Vice PresidentMar 25 '24Sale147.542,827417,0969,997Mar 27 01:29 PM
McMullen Michael R.CEO and PresidentMar 08 '24Sale150.0052,2977,844,550253,909Mar 12 02:37 PM
Gonsalves RodneyV.P., Corporate ControllerMar 07 '24Sale149.004,828719,34821,329Mar 08 12:05 PM
FIELDS HEIDIDirectorMar 05 '24Sale144.341,658239,31654,976Mar 07 10:38 AM
Binns PhilipSenior Vice PresidentDec 27 '23Sale139.782,880402,56612,824Dec 28 01:46 PM
Gonsalves RodneyV.P., Corporate ControllerDec 18 '23Sale137.691,500206,53826,133Dec 19 02:34 PM
Ancher-Jensen HenrikSr Vice PresidentDec 15 '23Option Exercise111.3611,7031,303,235108,835Dec 19 02:33 PM
Ancher-Jensen HenrikSr Vice PresidentDec 15 '23Sale138.3626,3313,643,15782,504Dec 19 02:33 PM
McMullen Michael R.CEO and PresidentDec 13 '23Option Exercise42.122,751115,872308,957Dec 15 05:08 PM
McMullen Michael R.CEO and PresidentDec 13 '23Sale130.002,751357,630306,206Dec 15 05:08 PM
McMullen Michael R.CEO and PresidentDec 07 '23Option Exercise42.1262,4672,631,110368,673Dec 08 02:59 PM
McMullen Michael R.CEO and PresidentDec 07 '23Sale130.0062,4678,120,710306,206Dec 08 02:59 PM